Calidi Biotherapeutics, Inc.
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $45.0K
- Net income
- -$19.9M
- Total assets
- $8.9M
- Market cap
- $3.3M
Source: SEC EDGAR · updated Jun 8, 2026
- Market cap
- $3.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2023
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Calidi Biotherapeutics, Inc..